ESMC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESMC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2025-05-15), Escalon Medical's Intrinsic Value: Projected FCF is $0.02. The stock price of Escalon Medical is $0.40. Therefore, Escalon Medical's Price-to-Intrinsic-Value-Projected-FCF of today is 20.0.
The historical rank and industry rank for Escalon Medical's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Escalon Medical was 21.00. The lowest was 2.76. And the median was 4.40.
The historical data trend for Escalon Medical's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Escalon Medical Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial |
![]() |
![]() |
-0.50 | -0.08 | -0.14 | 0.08 | -0.06 |
Escalon Medical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.05 | 0.09 | -0.06 | -0.05 | 0.02 |
For the Medical Devices subindustry, Escalon Medical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Escalon Medical's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Escalon Medical's Free Cash Flow(6 year avg) = $-0.14.
Escalon Medical's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Dec24) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | -0.13792 | + | 2.023 | * | 0.8) | / | 14.082 | |
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Escalon Medical (OTCPK:ESMC) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Escalon Medical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 0.40 | / | 0.021683930399413 | |
= | 18.45 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Escalon Medical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
David James Jacovini | director | 120 PINE STREET, PHILADELPHIA PA 19106 |
John Dogum | director | 1818 MARKET STREET, 35TH FLOOR, PHILADELPHIA PA 19103 |
Richard J Depiano | director | 435 DEVON PARK DRIVE, SUITE 100, WAYNE PA 19087 |
Lisa A Napolitano | director | 351 EAST CONESTOGA ROAD, WAYNE PA 19087 |
C Sean Closkey | director | 1700 MARKET STREET, 19TH FLOOR, PHILADELPHIA PA 19103 |
C Todd Trusk | director | 1410 RUSSELL ROAD, SUITE 100, WAYNE PA 19301 |
Robert Michael O'connor | officer: Chief Financial Officer | 53 SORREL RUN, MT. LAUREL NJ 08054 |
Anthony J Coppola | director | 1 NORTH NEW YORK ROAD, SMITHVILLE NJ 08205 |
Federman Jay L Md | director | 501 N. ESSEX AVENUE, NARBERTH PA 19072 |
Kwan William L G | director | 351 EAST CONESTOGA ROAD, WAYNE PA 19087 |
Mark Wallace | officer: Chief Operating Officer | 565 E SWEDESFORD ROAD, STE 200, WAYNE PA 19087 |
Fred G Choate | director | 601 DELSEA DRIVE, WASHINGTON TOWNSHIP NJ 08080 |
Depiano Richard J Jr | officer: President | 575 E. SWEDESFORD ROAD, SUITE 100, WAYNE PA 19087 |
Berkowitz David | officer: Principal Accounting Officer | 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087 |
Mark H Karsch | officer: CFO | 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087 |
From GuruFocus
By gurufocus • 05-15-2009
By gurufocus 10qk • 10-12-2010
By gurufocus 10qk • 05-20-2010
By gurufocus • 02-18-2009
By gurufocus 10qk • 11-16-2009
By gurufocus 10qk • 11-15-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.